SCHEMBL2129884

SCHEMBL2129884

N[C@H](Cc1cc(F)cc(F)c1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.57
PTGS1 P23219 2/20 0.57
PKM P14618 2/20 0.57
ALPI P09923 1/20 0.57
XIAP P98170 1/20 0.57
HSD17B10 Q99714 4/20 0.53
USP2 O75604 3/20 0.53
KDM4E B2RXH2 2/20 0.53
ALOX15 P16050 2/20 0.53
RECQL P46063 2/20 0.53
HIF1A Q16665 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
ADORA3 P0DMS8 2/20 0.53
EGFR P00533 1/20 0.53
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
HTR2A P28223 1/20 0.53
PTGS2 P35354 1/20 0.53
CYP2C9 P11712 2/20 0.52
MEN1 O00255 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188320 1.00 SLC7A5 (0.57) SLC7A5PTGS1PKMALPIXIAP
SCHEMBL188321 1.00 SLC7A5 (0.57) SLC7A5PTGS1PKMALPIXIAP
Glycine SCHEMBL28732579 0.93 SLC7A5 (0.50) SLC7A5PTGS1PKMALPIXIAP
SCHEMBL31524255 0.89 SLC7A5 (0.56) SLC7A5PTGS1PKMALPIXIAP
SCHEMBL10064656 0.89 SLC7A5 (0.56) SLC7A5PTGS1PKMALPIXIAP
SCHEMBL12803446 0.89 SLC7A5 (0.56) SLC7A5PTGS1PKMALPIXIAP
SCHEMBL845968 0.88 SLC7A5 (0.49) SLC7A5PTGS1PKMALPIXIAP
SCHEMBL31537504 0.88 SLC7A5 (0.49) SLC7A5PTGS1PKMALPIXIAP
SCHEMBL22944380 0.88 SLC7A5 (0.49) SLC7A5PTGS1PKMALPIXIAP
SCHEMBL845967 0.88 SLC7A5 (0.49) SLC7A5PTGS1PKMALPIXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160022636-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2016-01-28 US claimed
EP-2968240-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 Janssen Pharmaceutica, N.V. (BE) 2016-01-20 EP claimed
US-20140336216-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-11-13 US claimed
WO-2014152917-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 WO claimed
US-12122815-B2 GIP receptor agonist peptide compounds and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-10-22 US disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
US-20240034753-A1 THERAPEUTIC PEPTIDES COHBAR, INC. 2024-02-01 US disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 CN disclosed
US-11753445-B2 Therapeutic peptides COHBAR, INC. (US) 2023-09-12 US disclosed
US-11702652-B2 Enzymatic encoding methods for efficient synthesis of large libraries NUEVOLUTION A/S (DK) 2023-07-18 US disclosed
US-11702652-B2 Enzymatic encoding methods for efficient synthesis of large libraries NUEVOLUTION A/S (DK) 2023-07-18 US disclosed
US-20140336216-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-11-13 US disclosed
US-20120101037-A1 GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE ANALOGS HOFFMANN-LA ROCHE INC. 2012-04-26 US disclosed
EP-2341140-A1 Enzymatic encoding methods for efficient synthesis of large libraries Nuevolution A/S (DK) 2011-07-06 EP disclosed
EP-2336315-A2 Enzymatic encoding methods for efficient synthesis of large libraries Nuevolution A/S (DK) 2011-06-22 EP disclosed
EP-1957644-B1 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION AS (DK) 2010-12-01 EP disclosed
US-20090264300-A1 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION A/S (DK) 2009-10-22 US disclosed
US-20090264300-A1 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION A/S (DK) 2009-10-22 US disclosed
WO-2007062664-A2 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION A/S (DK) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264300-A1 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES RNGTT, DUT, EMG1 SLC7A5 1759/4885PTGS1 3108/4885PKM 3330/4885
US-20120101037-A1 GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE ANALOGS GIPR, GPR119, GLP1R SLC7A5 248/4885PTGS1 3381/4885PKM 1861/4885
US-12122815-B2 GIP receptor agonist peptide compounds and uses thereof GIPR, GLP1R, GPR119 SLC7A5 569/4885PTGS1 1157/4885PKM 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.